Do you have a problem with no-shows? #ABS1584 discusses telemedicine and care access during COVID-19. Case Western observed a 0% cancellation rate, <10% no-show rate, & 90% of scheduled telemed visits completed during COVID-19. #ACR20 #ACRbest @RheumNow https://t.co/uxzpfELDBG https://t.co/U2qrOTJZOq

• Risk Factors for Adverse Pregnancy Outcomes in Women with Spondyloarthritis: An…

My axSpA patients often ask me whether whether it's the weight loss that matters, or just exercise. Some answers from @rheum_cat - BMI itself does matter in AS. Another one chalked up for the obesity-related inflammasome! #ACR20 ABST1883 @RheumNow https://t.co/oMOqA8ypTt

Encouraging results on selective TK2 inhibitor in active PsA patients. ACR20 at week 16 of 53% and 63%, for low and high dose, compared to 32% placebo. NP, sinusitis, ha, rash most common AEs. Abst#L03 @RheumNow #ACR20 https://t.co/2UrOKFfnCL

Evidence that patients on biologics getting COVID less frequently should be interpreted with the knowledge that Abst#L02 shows increased shielding/risk mitigation of patients on biologics #ACR20 @RheumNow https://t.co/Dn1lUtd6hl

Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #ACR20 @RheumNow.

What are you telling rheum pts their risk is for COVID? MGH: higher unadjusted rate of mech ventilation, but not signif difference after adj for co-morbidities. Encouraging temporal improvement in care seen. Abst#L01 #ACR20 @Rheumnow https://t.co/BnPCtbo5Nj

Poster #L02 by @yatesmark1 et al shows #shielding in #IMID population on biologics may at least in part explain the lower risk of adverse #COVID19 outcomes in this group. Reinforces need for clear guidance on risk mitigation for patients. #ACR20 @RheumNow https://t.co/H4RMbfBrH2

• Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During …

Fatigue in RA - massive burden on patients. Intensity of fatigue in RA is a/w: pain, psychological distress, morning stiffness but not a/w: ESR, CRP, swollen joint count Fatigue needs its own consideration, separate to RA 'dx activity'! ESPOIR cohort #ACR20 ABST1727 @RheumNow https://t.co/Uqu5LDvSV6

Early RA window of opportunity: how hard, how early? Commonsense reassurance from ESPOIR: to get good outcomes at 10y (DAS28≤2.6, HAQ≤0.5): - csDMARD early - bDMARD second line is okay, within first 1y+ (analysis weighted for subsequent Rx exposure) #ACR20 ABST1717 @RheumNow https://t.co/kG9WYUYYef

High-intensity interval training (HIIT) benefits RA, & it looks more than just exercise-FM-CV health. Changes in T cell activity, muscle oxidative metabolism after HIIT in sedentary RA pts n=12 Looking forward to seeing more in this area @dukemedicine #ACR20 ABST1757 @RheumNow https://t.co/5gKheEUYJ6

Our RA patients are susceptible to a dangerous virus which runs rampant, but won't take the vaccine. Why won't patients have their flu shot? @McGillMed 40% hesitant despite public funding. Multiple levels influence; if we don't address, our pts suffer! #ACR20 ABST1740 @RheumNow https://t.co/1Yhr6I2L30

Test your ACR IQ and see where you place on our leaderboard. #ACR20 https://t.co/DKSq8gKTDb https://t.co/2mgg97ejPu

• https://bit.ly/36hztGB

Since MTX doesn’t work in cardiac prevention in non inflammatory pop’n (CIRT trial) should we use MTX in knee OA with inflammation? RCT n=344 w primary knee OA w swelling & pain. Rx MTX v glucosamine POSITIVE results #ACR20 abstr#1648 @RheumNow @CRASCRRheum #ACRbest https://t.co/7VptCPxKU8

#osteoarthritis Rx with #tanezumab - analgesic or DMOAD? RCT in knee OA of 3021 pts & only 1312 completed Rx. Tanezumab > improvement in pain v NSAIDs but NO diff in MCII and pt acceptable symptoms (PASS) over time #ACR20 #ACRbest abstr#1641 @RheumNow @CRASCRRheum https://t.co/x75ncz16uP